ALB

Business Context and Reporting Period

Company: Albemarle Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2003
Business Overview: Albemarle is a major worldwide producer of specialty chemicals, operating through two segments: Polymer Chemicals (flame retardants, catalysts, additives) and Fine Chemicals (pharmachemicals, agrichemicals, performance chemicals). The company employs approximately 3,000 people and operates manufacturing plants in the U.S. and Western Europe, with joint ventures in Asia, the Middle East, and Europe.

Key Financial Metrics (2003)

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 10.2% ($102.3 million) driven by acquisitions ($54.9 million in Polymer Chemicals, $1.9 million in Fine Chemicals), favorable foreign exchange movements ($56.6 million total), and higher shipments in flame retardants and agricultural chemicals.
• Margin Compression: Gross profit margin decreased 160 basis points to 21.5% due to significantly higher raw material and energy costs (up over $24 million compared to 2002) and unfavorable product mix/pricing in certain Fine Chemicals lines.
• Operating Profit Decline: Operating profit decreased 9.7% ($10.0 million) despite revenue growth, primarily due to higher input costs and special charges totaling $10.0 million (including a $7.5 million voluntary separation charge and a $2.5 million impairment charge on real estate).
• Acquisitions: The company completed three major acquisitions in 2003: Ethyl Corporation's antioxidants business ($27 million), Rhodia's phosphorus flame retardants business ($80 million), and Atofina's bromine fine chemicals business ($11 million).
• Restatements: 2002 financial statements were restated to move $3.5 million of revenue from Q4 2002 to Q1/Q2 2003 regarding a "bill and hold" transaction. Additionally, a $6.3 million deferred tax liability error from the 1994 spin-off was corrected.

Guidance, Outlook, and Risks

• Outlook: Management expects growth to continue in 2004 but anticipates moderation due to margin pressure and product maturation. The company plans to maintain a capital spending program of $50-$60 million annually.
• Strategic Focus: Continued investment in R&D (targeting 20% of portfolio from new products by 2006) and geographic expansion, particularly in Asia (80% sales increase in China in 2003).
• Key Risks:
  • Input Costs: Significant exposure to raw material (ethylene, chlorine, alumina trihydrate) and energy price volatility. A $1/MMBTU increase in natural gas reduces EPS by ~10 cents.
  • Competition: Intensifying competition from low-cost Asian and Indian manufacturers, particularly in generic pharmaceuticals and commodity-like additives.
  • Regulatory: Phase-out of methyl bromide (soil fumigant) by 2005 in the U.S. and environmental remediation liabilities (accrued at $29.1 million).
  • Foreign Exchange: Sales are sensitive to currency fluctuations; a 1% move in the Euro impacts annual sales by ~$3 million.

Investor Verification Checklist

• Restatement Impact: Verify the specific impact of the Q4 2002 revenue restatement on year-over-year growth comparisons.
• Acquisition Integration: Monitor the accretion timeline for the Rhodia and Ethyl acquisitions, which were expected to be accretive within one year.
• Raw Material Hedging: Review the effectiveness of natural gas futures contracts and long-term supply agreements in mitigating cost volatility.
• Environmental Liabilities: Assess the adequacy of the $29.1 million environmental accrual against potential future remediation costs, noting management's estimate of up to $10.5 million in potential excess costs.
• Pension Funding: Note the closure of the U.S. defined benefit plan to new employees in April 2004 and the impact of changing discount rate assumptions (reduced to 6.15%) on future obligations.